Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Paciucci

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
The Mount Sinai Journal of Medicine, New York|May 1, 1992
Immunotherapy of metastatic melanoma with interleukin-2P A Paciucci
Cancer Investigation|January 1, 1989
Antitumor activity of interleukin-2 without toxicity and other desiderataP A Paciucci
AIDS Research|January 1, 1983
Hypothesis: AIDS: AAIDS (acquired autoimmune immunodeficiency syndrome)?P A Paciucci, J F Holland
Annals of Internal Medicine|November 1, 1986
Mitoxantrone and hepatic toxicityP A Paciucci, N T Sklarin
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1984
Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactionsS Macphail, P A Paciucci, O Stutman
Seminars in Oncology|September 1, 1984
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemiaP A Paciucci, J Cuttner, J F Holland
American Journal of Hematology|September 1, 1990
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemiaP A Paciucci, J Cuttner, J F Holland
La Ricerca in Clinica E in Laboratorio|January 1, 1977
Immunological reactivity of peripheral lymphocytes in kidney transplant patientsP A Paciucci, E Renna, C Nesci, et al.
American Journal of Clinical Oncology|August 1, 1989
Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphomaP A Paciucci, J C Crown, J F Holland
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1989
Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancerP A Paciucci, J F Holland, O Glidewell, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
The Mount Sinai Journal of Medicine, New York|May 1, 1992
Immunotherapy of metastatic melanoma with interleukin-2P A Paciucci
Cancer Investigation|January 1, 1989
Antitumor activity of interleukin-2 without toxicity and other desiderataP A Paciucci
AIDS Research|January 1, 1983
Hypothesis: AIDS: AAIDS (acquired autoimmune immunodeficiency syndrome)?P A Paciucci, J F Holland
Annals of Internal Medicine|November 1, 1986
Mitoxantrone and hepatic toxicityP A Paciucci, N T Sklarin
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1984
Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactionsS Macphail, P A Paciucci, O Stutman
Seminars in Oncology|September 1, 1984
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemiaP A Paciucci, J Cuttner, J F Holland
American Journal of Hematology|September 1, 1990
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemiaP A Paciucci, J Cuttner, J F Holland
La Ricerca in Clinica E in Laboratorio|January 1, 1977
Immunological reactivity of peripheral lymphocytes in kidney transplant patientsP A Paciucci, E Renna, C Nesci, et al.
American Journal of Clinical Oncology|August 1, 1989
Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphomaP A Paciucci, J C Crown, J F Holland
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1989
Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancerP A Paciucci, J F Holland, O Glidewell, et al.
Pageof 4